Wire · opportunities
Two Investigational Paths in GAD: Company-Reported Results on DT120 ODT and SNTX-2643
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 September 2026 · Fusion42 review
Definium Therapeutics reported positive Phase 3 results for DT120 ODT in treating generalized anxiety disorder (GAD) with significant symptom improvement, while Sensorium Therapeutics presented Phase 1a safety and pharmacodynamic data for SNTX-2643, a serotonin modulator under early investigation. Neither therapy is FDA-approved yet, but Definium plans a pre-NDA meeting in late 2026.
This Wire brief sits within Fusion42's coverage of Mental Health.
◆ ◆ The Wire takeaway
You face a near-term regulatory window as Definium prepares for FDA review after successful Phase 3 trials of DT120 ODT. Start aligning clinical development and market access plans now to capitalise on the emerging approval path for psychedelic-derived anxiety treatments.
◆ Coverage
1 source · 29 Sep 2026
◆ Related on Wire
◆ Topics